Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Blood Mononuclear Cells for Secondary Poor Graft Function
NCT06792682Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umbilical cord blood mononuclear cells in poor graft function (PGF), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Safety assessment at 24 months. Started Feb 2025; status: recruiting.
02
Drugs
umbilical cord blood mononuclear cells
03
Conditions
poor graft function (PGF)
Beyond the preview
Go deeper on NCT06792682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792682.